Evidence map›Paper›PMID 33110361›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2020

E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells.

Esra Aydemİr Çoban, Didem Tecİmel, Ezgi KaŞikci, Ömer Faruk Bayrak, Fikrettin Şahİn

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Esra Aydemİr ÇobanDepartment of Genetics and Bioengineering, Engineering Faculty, Yeditepe University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-6965-2838
Didem TecİmelDepartment of Genetics and Bioengineering, Engineering Faculty, Yeditepe University, İstanbul Turkey.ORCID https://orcid.org/0000-0002-0776-1238
Ezgi KaŞikciDepartment of Genetics and Bioengineering, Engineering Faculty, Yeditepe University, İstanbul Turkey.ORCID https://orcid.org/0000-0003-4570-3781
Ömer Faruk BayrakDepartment of Genetics and Bioengineering, Engineering Faculty, Yeditepe University, İstanbul Turkey.ORCID https://orcid.org/0000-0001-7562-6604
Fikrettin ŞahİnDepartment of Genetics and Bioengineering, Engineering Faculty, Yeditepe University, İstanbul Turkey.ORCID https://orcid.org/0000-0003-1503-5567
Yeditepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) pathology is known for its uncontrollable progress due to highly invasive characteristics and refractory behavior against existing chemotherapies. The aberrant expression of CDH1 (expresses the protein E-cadherin) is associated with increased overall survival in various cancers, however, E-cadherin expression in PDAC progression has remained elusive. We investigated the impact of exogenously elevated E-cadherin levels on the tumorigenicity of transduced low grade and metastatic PDAC cell lines, Panc-1 and AsPC-1, respectively. Constitutive expression of E-cadherin promoted a more hybrid E/M state in AsPC-1 cells, while it was associated with the acquisition of a more epithelial-like state in Panc1 cells. Our study suggests that E-cadherin may play differential roles in determining the metastatic characteristics of primary and metastatic pancreatic cancer cells.

Indexed as

AsPC1CRISPR/dCas9 activationE-cadherinPanc-1pancreas cancer

Identifiers

PMID33110361
PMCPMC7585161
OpenAlexW3094757161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.